Faraday Pharmaceuticals to Host KOL Webinar on the Unmet Need in the Prevention of Ischemia-Reperfusion Injury in Acute STEMI
July 16, 2024 12:40 ET
|
Faraday Pharmaceuticals
SEATTLE, July 16, 2024 (GLOBE NEWSWIRE) -- Faraday Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the prevention of heart failure by reducing myocardial damage...
Faraday Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 Iocyte AMI-3 Trial of FDY-5301
June 11, 2024 08:30 ET
|
Faraday Pharmaceuticals
2,300 patients in trial enrolled ahead of schedule12-month follow up period underway, with topline data anticipated in 2H 2025Trial designed with 90% power to detect a 30% reduction in the primary...
Faraday Pharmaceuticals Announces Agreement with FDA on Interim Analysis of Phase 3 IOCYTE AMI-3 Trial Data and EU Notice of Intention to Grant Patent
January 04, 2024 15:05 ET
|
Faraday Pharmaceuticals
Interim analysis estimated to occur in late Q2 2024 and will be based on at least 50% of anticipated primary outcomesPivotal Phase 3 trial continues to progress with over 75% of initially-planned...
Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 3 Trial for Myocardial Infarction
May 10, 2022 07:30 ET
|
Faraday Pharmaceuticals
SEATTLE, May 10, 2022 (GLOBE NEWSWIRE) -- Faraday Pharmaceuticals, Inc., today announced the enrollment of the first patient in its Iocyte AMI-3 study — a Phase 3 clinical trial assessing the...
Faraday Pharmaceuticals Announces Publication of Results from its Phase 2 Study of FDY-5301 for the Treatment of Reperfusion Injury Following a STEMI Heart Attack
December 27, 2021 08:30 ET
|
Faraday Pharmaceuticals
SEATTLE, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Faraday Pharmaceuticals, Inc., a muscle health-focused biopharmaceutical company developing therapeutics to treat patients experiencing potentially life...
Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 2 Study for ICU-Acquired Weakness
October 14, 2021 05:30 ET
|
Faraday Pharmaceuticals
SEATTLE, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Faraday Pharmaceuticals, Inc., a biopharmaceutical company dedicated to improving the quality of life for patients experiencing potentially life-changing...